FDA granted Orphan Drug designation to AVX-470 from Avaxia to treat pediatric ulcerative colitis (UC). The oral inhibitor of tumor necrosis factor (TNF) alpha completed a Phase Ib trial in adults with UC (see BioCentury,...

A double-blind, placebo-controlled, international Phase Ib trial in 36 patients with active UC showed that once-daily 0.2, 1.6 and 3.5 g doses of oral AVX-470 for 28 days were well tolerated with no treatment-related serious...

Avaxia began a double-blind, placebo-controlled, international Phase Ib trial to evaluate 0.2, 1.6 and 3.5 g oral AVX-470 daily for 28 days in about 24 patients with active UC. Avaxia Biologics Inc. , Lexington, Mass.  ...

The companies partnered to develop an assay to evaluate the effect of Avaxia's AVX-470 in treating gastrointestinal damage following radiation exposure in preclinical models and in humans. The companies will use Courtagen's Avantra Q400 Protein...

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Avaxia a two-year, $2.9 million contract for preclinical testing of AVX-470 to treat gastrointestinal injury caused by radiation exposure when given 24 hours after exposure. The...